|Other names||IMAB362; Claudiximab|
|(what is this?)|
Zolbetuximab (development code IMAB362) is an experimental monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. IMAB362 was developed by Ganymed Pharmaceuticals AG.
- "Our mission - Ganymed Pharmaceuticals GmbH - Ganymed Pharmaceuticals GmbH". www.ganymed-pharmaceuticals.de.
- "A Study of Zolbetuximab (IMAB362)". clinicaltrials.gov. 19 November 2021.
- "Antibody Shines in Advanced Gastric Cancer". medpagetoday.com. 5 June 2016.